(Q38079792)

28 August 2017

title

Trophic factor gene therapy for Parkinson's disease (English)

1 reference

28 August 2017

0 references

1 reference

1

Jeffrey H Kordower

1 reference

28 August 2017

Anders Bjorklund

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

28

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

96-109

1 reference

Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system

28 August 2017

cites work

1 reference

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

21 January 2018

1 reference

Improved survival of embryonic porcine dopaminergic neurons in coculture with a conditionally immortalized GDNF-producing hippocampal cell line

21 January 2018

1 reference

GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro

21 January 2018

1 reference

Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro

21 January 2018

1 reference

Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo

21 January 2018

1 reference

Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons.

21 January 2018

1 reference

Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor

21 January 2018

1 reference

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

21 January 2018

1 reference

Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys

21 January 2018

1 reference

Functional recovery in parkinsonian monkeys treated with GDNF

21 January 2018

1 reference

Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys

21 January 2018

1 reference

Point source concentration of GDNF may explain failure of phase II clinical trial

21 January 2018

1 reference

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

21 January 2018

1 reference

Crossroads in GDNF therapy for Parkinson's disease

21 January 2018

1 reference

Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal

21 January 2018

1 reference

Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach

21 January 2018

1 reference

Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce l-dopa

21 January 2018

1 reference

Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted with genetically-modified human astrocytes

21 January 2018

1 reference

Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease

21 January 2018

1 reference

Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model

21 January 2018

1 reference

Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?

21 January 2018

1 reference

Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease

21 January 2018

1 reference

Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway.

21 January 2018

1 reference

Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates

21 January 2018

1 reference

Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease

21 January 2018

1 reference

Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model

21 January 2018

1 reference

Dopaminergic neurons protected from degeneration by GDNF gene therapy

21 January 2018

1 reference

Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain

21 January 2018

1 reference

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

21 January 2018

1 reference

Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression

21 January 2018

1 reference

Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression

21 January 2018

1 reference

Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease

21 January 2018

1 reference

Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?

21 January 2018

1 reference

Adeno-associated virus serotypes: vector toolkit for human gene therapy

21 January 2018

1 reference

Immune responses to AAV capsid: are mice not humans after all?

21 January 2018

1 reference

Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats

21 January 2018

1 reference

Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease

21 January 2018

1 reference

Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).

21 January 2018

1 reference

Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys

21 January 2018

1 reference

Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys

21 January 2018

1 reference

Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease

21 January 2018

1 reference

Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF.

21 January 2018

1 reference

Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector

21 January 2018

1 reference

Lentiviral gene transfer to the nonhuman primate brain

21 January 2018

1 reference

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

21 January 2018

1 reference

alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

21 January 2018

1 reference

Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease

21 January 2018

1 reference

GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease

21 January 2018

1 reference

Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?

21 January 2018

1 reference

Neurturin, a relative of glial-cell-line-derived neurotrophic factor

21 January 2018

1 reference

Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons

21 January 2018

1 reference

Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease

21 January 2018

1 reference

Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease

21 January 2018

1 reference

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

21 January 2018

1 reference

Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease

21 January 2018

1 reference

Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct.

21 January 2018

1 reference

Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point

21 January 2018

1 reference

Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease

21 January 2018

1 reference

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

21 January 2018

1 reference

Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum

21 January 2018

1 reference

Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

21 January 2018

1 reference

Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease

21 January 2018

1 reference

Localized striatal delivery of GDNF as a treatment for Parkinson disease

21 January 2018

1 reference

Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases

21 January 2018

1 reference

Neurotrophic factors: from molecule to man.

21 January 2018

1 reference

Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys

21 January 2018

1 reference

Axonal transport defects: a common theme in neurodegenerative diseases

21 January 2018

1 reference

Role of axonal transport in neurodegenerative diseases

21 January 2018

1 reference

Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.25344

1 reference

28 August 2017

1 reference